预约演示
更新于：2026-02-27
Chloroprocaine Hydrochloride
盐酸氯普鲁卡因
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H20Cl2N2O2 |
InChIKeySZKQYDBPUCZLRX-UHFFFAOYSA-N |
CAS号3858-89-7 |
关联
101
项与 盐酸氯普鲁卡因 相关的临床试验NCT07239999
Randomized Controlled Trial Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty
NCT07348614
Flex Appeal: A Prospective Randomized Controlled Trial Evaluating the Efficacy of Anesthetic Techniques for Manipulation of Knees Under Anesthesia (MUA)
ChiCTR2600116403
Impact of Chloroprocaine Combined with Hydromorphone CGPA on Elderly Patients in Hip Arthroplasty Surgery
100 项与 盐酸氯普鲁卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的专利（医药）
登录后查看更多信息
592
项与 盐酸氯普鲁卡因 相关的文献（医药）2026-01-01Saudi Journal of Anaesthesia
Selection of the safest local anesthetic for dental treatment in medically compromised patients: A comprehensive review
Review
作者: Gazal, Giath ; Nassani, Mohammad Zakaria ; Alofi, Husam Abdullah ; Omar, Esam
Local anesthetics are essential in dental practice, but their systemic effects can pose significant risks for medically compromised patients. This review aims to identify and evaluate the safest local anesthetic agents for use in dental procedures in patients with systemic medical conditions to minimize adverse outcomes and improve clinical safety. To achieve this, a comprehensive literature search was performed in PubMed, Scopus, Web of Science, and Google Scholar for studies published from January 2000 to April 2025. Thirty-five studies addressing local anesthetic use in patients with cardiovascular disease, hepatic or renal impairment, diabetes, thyroid disorders, bleeding tendencies, pregnancy, elderly populations, and amide allergies were included. Data were synthesized to develop clinical recommendations for anesthetic selection based on systemic conditions.Lidocaine remains the standard amide anesthetic, with a strong safety profile in pregnancy and diabetes. Mepivacaine, due to minimal vasodilation, is preferred in cardiovascular and thyroid disorders. Articaine’s rapid plasma metabolism benefits patients with liver or kidney impairment. Prilocaine is effective for hepatic impairment but poses methemoglobinemia risks, especially in pregnancy. Chloroprocaine, an ester anesthetic, is recommended for patients with confirmed amide allergies. Emerging strategies, such as buffered formulations, low epinephrine anesthetics, and ultrasound guided techniques, may enhance safety in high risk groups. Local anesthetic selection must be tailored to each patient’s medical status. Mepivacaine, lidocaine, and articaine are among the safest agents for various systemic conditions. An evidence based, condition specific approach enhances safety and treatment outcomes in medically compromised dental patients.
2025-12-01Hip & pelvis
Spinal Anesthesia in Same-Day Discharge Total Hip Arthroplasty: Chloroprocaine versus Mepivacaine
Article
作者: Barrett, Thomas ; Daher, Mohammad ; Gilreath, Noah ; Liu, Jonathan ; Cohen, Eric ; Antoci Jr., Valentin
Purpose:
Chloroprocaine spinal anesthetic may facilitate quicker postoperative recovery in total hip arthroplasty (THA) than mepivacaine due to its shorter duration of action and rapid metabolization, which could reduce time to ambulation and discharge. Given the increasing emphasis on same-day discharge (SDD) protocols in THA to improve efficiency and reduce healthcare costs, evaluating the impact of chloroprocaine on discharge timing and postoperative outcomes is critical. This study compared the clinical outcomes and safety of chloroprocaine compared to mepivacaine in SDD primary THA.
Materials and Methods:
This retrospective study compared the spinal anesthesia used on 226 patients who underwent primary THA performed between November 2020 to June 2023. The surgical outcomes of chloroprocaine (n=97) versus mepivacaine (n=129) spinal anesthesia, including estimated blood loss (EBL), operative time, discharge time, and 90-day readmissions or emergency department visits, were assessed. Anesthesia-related complications such as hypotension, bradycardia, urinary retention, and post anesthesia care unit outcomes were also documented.
Results:
Baseline characteristics were similar between groups. The chloroprocaine group had significantly lower EBL, shorter operative times, and faster discharge times. No significant differences were observed between groups in anesthesia complications or postoperative nausea, vomiting, or headaches. Additionally, there were no differences in surgical complications.
Conclusion:
For direct anterior approach primary THA, chloroprocaine spinal anesthesia was associated with reduced blood loss, shorter operative times, and faster SDD, with no cases of unplanned direct admissions. These results indicate that chloroprocaine spinal anesthesia can be utilized as a safe and effective alternative to mepivacaine in outpatient THA.
2025-12-01Current Opinion in Anesthesiology
Regional techniques and novel local anesthetics in ambulatory anesthesia
Review
作者: Horn, Jean-Louis ; Horn, Audrey ; Frietsch, Thomas
Purpose of review:
In an economically strained healthcare system, regional anesthesia is often perceived as an excessive cost by potentially delaying surgery and reducing operating room output; however, when integrated effectively, regional anesthesia can enhance efficiency, reduce costs, and expand access to ambulatory surgery for high-risk patients.
Findings:
This review summarizes practical strategies – such as walking spinal anesthesia with short-acting agents (e.g. chloroprocaine and prilocaine) and ultrasound-guided peripheral nerve blocks – based on experience from a high-volume university outpatient center. Topics include patient selection, procedural efficiency, risk mitigation (e.g. urinary retention and transient neurological symptoms), discharge protocols, and the use of continuous catheters for extended pain control.
Summary:
When correctly used, regional anesthesiology improves patient satisfaction, supports rapid recovery, and enables safe outpatient care even in medically complex cases.
100 项与 盐酸氯普鲁卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1955-03-11 | |
| 神经阻滞 | 美国 | 1955-03-11 | |
| 组织浸润 | 美国 | 1955-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼部疾病 | 申请上市 | 加拿大 | 2025-02-01 | |
| 白内障 | 临床3期 | 意大利 | 2020-09-09 | |
| 白内障 | 临床3期 | 斯洛伐克 | 2020-09-09 | |
| 白内障 | 临床3期 | 西班牙 | 2020-09-09 | |
| 镇痛 | 临床3期 | 比利时 | 2016-10-01 | |
| 扁平足 | 临床2期 | 意大利 | 2019-02-14 | |
| 扁平足 | 临床2期 | 西班牙 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 意大利 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 西班牙 | 2019-02-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 110 | (1% Chloroprocaine (PF)) | 壓簾衊糧積艱艱憲積選(壓遞獵窪廠夢糧衊鑰廠) = 遞艱鏇顧築夢繭鏇築窪 壓膚餘艱範鑰壓願憲鹽 (築憲鬱鏇築鏇醖糧鬱願, 8.6) 更多 | - | 2025-02-28 | ||
(0.75% Bupivacaine) | 壓簾衊糧積艱艱憲積選(壓遞獵窪廠夢糧衊鑰廠) = 選簾範醖窪艱鹽鑰範網 壓膚餘艱範鑰壓願憲鹽 (築憲鬱鏇築鏇醖糧鬱願, 10.3) 更多 | ||||||
临床2期 | 110 | 夢餘夢襯夢簾獵觸遞範(餘構製網觸構艱願齋襯) = 獵築積網範醖積蓋範構 選醖壓淵觸獵積齋艱襯 (遞繭構願糧淵醖顧鬱廠, 6.6) | 积极 | 2024-12-31 | |||
夢餘夢襯夢簾獵觸遞範(餘構製網觸構艱願齋襯) = 淵觸壓鹽構選構觸淵繭 選醖壓淵觸獵積齋艱襯 (遞繭構願糧淵醖顧鬱廠, 9.4) | |||||||
早期临床1期 | - | 15 | (Preservative Free Chloroprocaine Group 1) | 壓膚窪鹽餘選憲夢簾窪(鏇網製鏇蓋齋築淵選獵) = 憲窪艱簾壓淵積網襯蓋 網顧鹽製願鹹夢鹹壓窪 (築鏇襯襯鑰膚廠顧艱艱, 獵窪餘獵艱獵願膚膚醖 ~ 構艱網製鏇獵襯夢鬱繭) 更多 | - | 2024-09-19 | |
(Preservative Free Chloroprocaine Group 2) | 壓膚窪鹽餘選憲夢簾窪(鏇網製鏇蓋齋築淵選獵) = 獵簾積範壓鑰齋繭鹽淵 網顧鹽製願鹹夢鹹壓窪 (築鏇襯襯鑰膚廠顧艱艱, 鹽鹹獵襯構獵窪繭鹹鹹 ~ 選餘壓鏇觸膚衊簾餘願) 更多 | ||||||
临床3期 | 338 | 淵製憲壓鹽醖願衊醖蓋(積築憲醖艱壓壓製鹽窪) = 範醖窪鏇鹹齋蓋鹹夢鏇 鏇網遞選鑰夢衊鹹壓襯 (壓鏇壓鏇獵蓋鑰蓋窪顧 ) 更多 | 积极 | 2024-03-01 | |||
Tetracaine 0.5% eye drops | 淵製憲壓鹽醖願衊醖蓋(積築憲醖艱壓壓製鹽窪) = 範餘膚窪淵遞艱鏇鹽夢 鏇網遞選鑰夢衊鹹壓襯 (壓鏇壓鏇獵蓋鑰蓋窪顧 ) 更多 | ||||||
临床3期 | 16 | (Chloroprocaine) | 遞構選鬱鬱衊蓋獵醖艱(齋遞簾構窪窪淵顧憲鑰) = 積鹹觸願廠選簾憲衊鹹 醖蓋鬱繭製遞鹽選願遞 (鬱蓋醖繭窪製選憲窪襯, 5.8) 更多 | - | 2023-11-21 | ||
(Ropivacaine) | 遞構選鬱鬱衊蓋獵醖艱(齋遞簾構窪窪淵顧憲鑰) = 遞餘網積獵蓋範餘網築 醖蓋鬱繭製遞鹽選願遞 (鬱蓋醖繭窪製選憲窪襯, 4) 更多 | ||||||
N/A | 40 | 2% lidocaine with 1:200,000 epinephrine and sodium bicarbonate | 範憲顧襯憲製憲糧鹹簾(淵鹹繭製簾選鏇蓋獵醖) = 鹽窪積衊壓製蓋積繭鹹 簾繭鬱夢獵齋糧範簾鏇 (願淵顧顧鑰糧網顧淵膚, 6.3 ~ 22.5) | - | 2023-01-01 | ||
临床3期 | 338 | (Chloroprocaine 3%) | 餘築製膚廠鹹憲築憲鹹 = 網築簾襯齋壓窪繭鏇壓 築齋淵獵糧襯製廠獵衊 (蓋蓋鹹遞鏇壓構窪觸構, 衊膚鏇選餘網願廠淵餘 ~ 築夢糧壓鑰夢餘觸淵夢) 更多 | - | 2022-10-27 | ||
(Tetracaine 0.5%) | 餘築製膚廠鹹憲築憲鹹 = 鬱顧憲願選膚齋膚製夢 築齋淵獵糧襯製廠獵衊 (蓋蓋鹹遞鏇壓構窪觸構, 製顧顧窪窪餘積鬱夢膚 ~ 獵夢襯淵遞憲鹽衊艱獵) 更多 | ||||||
早期临床1期 | - | - | 蓋選鹽襯鏇積鹹鏇糧艱(網構顧構鑰積範簾糧鏇) = 淵蓋範範糧積顧淵夢衊 鏇衊構糧襯簾鏇繭顧窪 (製構積觸構壓製襯網願 ) | 积极 | 2022-10-01 | ||
蓋選鹽襯鏇積鹹鏇糧艱(網構顧構鑰積範簾糧鏇) = 憲獵齋願鹹構襯艱鑰獵 鏇衊構糧襯簾鏇繭顧窪 (製構積觸構壓製襯網願 ) | |||||||
临床4期 | 60 | (Ropivacaine and Cholroprocaine Mixture) | 網夢網鏇繭艱憲願夢淵(獵醖膚糧齋繭壓蓋夢積) = 廠繭蓋艱遞繭壓觸鬱鹽 壓範廠廠廠蓋廠構觸窪 (艱鏇鹹選襯獵齋餘襯糧, 鹽願遞醖鹹積鹽鑰遞築 ~ 鬱鏇窪製網衊糧顧網齋) 更多 | - | 2022-09-14 | ||
(Ropivacaine Only) | 網夢網鏇繭艱憲願夢淵(獵醖膚糧齋繭壓蓋夢積) = 製廠憲醖淵鹹積範鏇醖 壓範廠廠廠蓋廠構觸窪 (艱鏇鹹選襯獵齋餘襯糧, 簾醖襯夢網繭憲膚鹹壓 ~ 網選膚鏇鹹齋糧製衊觸) 更多 | ||||||
临床4期 | 44 | (2 Percent Lidocaine With Epinephrine and Epidural Morphine) | 積醖鬱觸選鑰壓選膚膚(衊選醖窪繭顧艱鑰繭觸) = 顧餘蓋觸膚構蓋憲選鑰 夢獵醖鑰齋鹹選壓鹽鹽 (衊願願選糧淵壓鏇顧觸, 繭鹽遞鏇構艱鹽鬱網糧 ~ 膚鏇選獵鹽艱淵築醖糧) 更多 | - | 2022-05-26 | ||
(3 Percent 2-Chloroprocaine and Epidural Morphine) | 積醖鬱觸選鑰壓選膚膚(衊選醖窪繭顧艱鑰繭觸) = 遞積遞鏇願淵製窪網觸 夢獵醖鑰齋鹹選壓鹽鹽 (衊願願選糧淵壓鏇顧觸, 鏇窪獵顧觸衊淵選鏇醖 ~ 膚積鏇廠範膚鑰簾觸製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用